BriaCell Therapeutics Files Q3 2024 10-Q
Ticker: BCTXZ · Form: 10-Q · Filed: Jun 14, 2024 · CIK: 1610820
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: BCTX
TL;DR
BriaCell's Q3 10-Q is in, showing financial snapshots from early 2024 vs. mid-2023. Check for cash burn and equity changes.
AI Summary
BriaCell Therapeutics Corp. filed its 10-Q for the period ending April 30, 2024. The company reported financial results and operational updates. Key financial figures and balance sheet items as of January 31, 2024, and July 31, 2023, were detailed, including common stock and additional paid-in capital.
Why It Matters
This filing provides investors with the latest financial health and operational status of BriaCell Therapeutics, crucial for understanding its ongoing development and market position.
Risk Assessment
Risk Level: medium — Biotech companies often carry higher risk due to clinical trial outcomes, regulatory approvals, and funding needs.
Key Numbers
- N/A — Revenue (Specific revenue figures for the quarter are not detailed in the provided header information.)
- N/A — Net Loss (Specific net loss figures for the quarter are not detailed in the provided header information.)
- N/A — Cash and Equivalents (Specific cash and equivalents figures are not detailed in the provided header information.)
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Filer of the 10-Q
- 2024-04-30 (date) — End of reporting period
- 2024-01-31 (date) — Balance sheet date
- 2023-07-31 (date) — Prior fiscal year end
FAQ
What were BriaCell's total assets as of April 30, 2024?
The provided header information does not contain specific figures for total assets as of April 30, 2024.
What was the company's cash burn rate for the quarter ending April 30, 2024?
The header information does not detail the cash burn rate for the specified period.
Did BriaCell Therapeutics issue any new shares or debt during the reported period?
The header information indicates the presence of common shares and warrants but does not specify any new issuances during the period.
What is the company's fiscal year end?
BriaCell Therapeutics Corp.'s fiscal year ends on July 31.
What was the company's former name?
The company's former name was Ansell Capital Corp., with a date of name change on June 13, 2014.
Filing Stats: 4,523 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2024-06-14 16:10:39
Key Financial Figures
- $35,964 — ue of the First BC Therapeutics Option, $35,964, has been reclassified to the investmen
Filing Documents
- form10-q.htm (10-Q) — 866KB
- ex31-1.htm (EX-31.1) — 18KB
- ex31-2.htm (EX-31.2) — 18KB
- ex32-1.htm (EX-32.1) — 7KB
- ex32-2.htm (EX-32.2) — 7KB
- 0001493152-24-023867.txt ( ) — 4750KB
- bctx-20240430.xsd (EX-101.SCH) — 33KB
- bctx-20240430_cal.xml (EX-101.CAL) — 39KB
- bctx-20240430_def.xml (EX-101.DEF) — 188KB
- bctx-20240430_lab.xml (EX-101.LAB) — 270KB
- bctx-20240430_pre.xml (EX-101.PRE) — 239KB
- form10-q_htm.xml (XML) — 811KB
Financial Information
Part I. Financial Information 3 Item 1.
Financial Statements
Financial Statements 3 Condensed Consolidated Balance Sheets as of April 30, 2024 (unaudited) and July 31, 2023 (unaudited) 3 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended April 30, 2024 4 Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity for the Three and Nine Months ended April 30, 2024 5 Unaudited Condensed Consolidated Statement of Cash Flows for the Nine Months ended April 30, 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.
Quantitative and Qualitative Disclosures Regarding Market Risk
Quantitative and Qualitative Disclosures Regarding Market Risk 22 Item 4.
Controls and Procedures
Controls and Procedures 23
Other Information
Part II. Other Information 24 Item 1.
Legal Proceedings
Legal Proceedings 24 Item 1A.
Risk Factors
Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 24
Signatures
Signatures 25 2 PART I-FINANCIAL INFORMATION Item 1. Financial Statements BRIACELL THERAPEUTICS CORP. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS April 30, 2024 July 31, 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 935,694 $ 21,251,092 Amounts receivable 15,233 18,873 Prepaid expenses 4,579,065 5,678,542 Total current assets 5,529,992 26,948,507 NON-CURRENT ASSETS: Investments 2 2 Equity investment in BC Therapeutics 469,658 - Intangible assets, net 203,614 215,068 Total non-current assets 673,274 215,070 Total assets $ 6,203,266 $ 27,163,577 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables $ 6,422,402 $ 1,123,739 Accrued expenses and other payables 335,357 677,718 Total current liabilities 6,757,759 1,801,457 NON-CURRENT LIABILITIES: Warrant liability 5,678,505 29,139,301 Total non-current liabilities 5,678,505 29,139,301 SHAREHOLDERS' DEFICIT: Share Capital of no par value - Authorized: unlimited at April 30, 2024 and July 31, 2023, Issued and outstanding: 15,981,726 shares April 30, 2024 and July 31, 2023, respectively 69,591,784 69,591,784 Share-based payment reserve 8,811,369 7,421,950 Accumulated other comprehensive loss ( 138,684 ) ( 138,684 ) Non-controlling Interest ( 267,935 ) - Accumulated deficit ( 84,229,532 ) ( 80,652,231 ) Total shareholders' deficit ( 6,232,998 ) ( 3,777,181 ) Total liabilities and shareholders' deficit $ 6,203,266 $ 27,163,577 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 BRIACELL THERAPEUTICS CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED APRIL 30, 2024 (Unaudited) Three months ended Nine months ended April 30, April 30, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Operating Expenses: Research and deve